Mariani Marco Valerio, Pierucci Nicola, La Fazia Vincenzo Mirco, Cipollone Pietro, Micillo Marco, D'Amato Andrea, Fanisio Francesca, Ammirati Giuseppe, Salagundla Nethuja, Lavalle Carlo, Perrone Marco Alfonso
Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX 78705, USA.
J Cardiovasc Dev Dis. 2024 Aug 7;11(8):243. doi: 10.3390/jcdd11080243.
Pregnancy entails notable physiological alterations and hormonal fluctuations that affect the well-being of both the fetus and the mother. Cardiovascular events and arrhythmias are a major concern during pregnancy, especially in women with comorbidities or a history of arrhythmias. This paper provides an overview of the prevalence, therapies, and prognoses of different types of arrhythmias during pregnancy. The administration of antiarrhythmic drugs (AADs) during pregnancy demands careful consideration because of their possible effect on the mother and fetus. AADs can cross the placenta or be present in breast milk, potentially leading to adverse effects such as teratogenicity, growth restriction, or premature birth. The safety profiles of different classes of AADs are discussed. Individualized treatment approaches and close monitoring of pregnant women prescribed AADs are essential to ensure optimal maternal and fetal outcomes.
怀孕会带来显著的生理变化和激素波动,这些会影响胎儿和母亲的健康。心血管事件和心律失常是孕期的主要关注点,尤其是在患有合并症或有心律失常病史的女性中。本文概述了孕期不同类型心律失常的患病率、治疗方法和预后。由于抗心律失常药物(AADs)可能对母亲和胎儿产生影响,在孕期使用时需要仔细考虑。AADs可穿过胎盘或存在于母乳中,可能导致致畸性、生长受限或早产等不良反应。文中讨论了不同类别的AADs的安全性。对于开具了AADs的孕妇,个体化的治疗方法和密切监测对于确保最佳的母婴结局至关重要。